Verquvo (vericiguat) is used for symptomatic chronic heart failure in adults with reduced ejection fraction who are stabilized after a recent heart failure decompensation event.
Adolescent idiopathic scoliosis is the most prevalent form of the condition, affecting about 2% of teens. Approximately seven times more teenage girls than boys are afflicted with it, says the report released Monday.